Kazia Therapeutics Ltd (KZA)

1.420
-0.005(-0.35%)
  • Volume:
    30,301
  • Bid/Ask:
    1.400/1.425
  • Day's Range:
    1.400 - 1.425

KZA Overview

Prev. Close
1.425
Day's Range
1.4-1.425
Revenue
15.25M
Open
1.42
52 wk Range
0.77-1.88
EPS
-0.08
Volume
30,301
Market Cap
188.89M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
45,218
P/E Ratio
-
Beta
1.99
1-Year Change
54.09%
Shares Outstanding
132,552,209
Next Earnings Date
-
What is your sentiment on Kazia Therapeutics Ltd?
or
Market is currently closed. Voting is open during market hours.

Kazia Therapeutics Ltd News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyBuyStrong Buy
Technical IndicatorsBuyStrong BuyBuyBuyStrong Buy
SummaryStrong BuyStrong BuyStrong BuyBuyStrong Buy

Kazia Therapeutics Ltd Company Profile

Kazia Therapeutics Ltd Company Profile

Employees
12
Market
Australia

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

Read More
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.